Ian Chau, MD

Articles

Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer

March 14th 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.

Dr. Chau on Analysis of Asian and Western Patients With Gastric/GEJ Cancer

Ian Chau, MD

February 22nd 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses an analysis of Asian and Western patients with chemotherapy-refractory gastric/gastroesophageal junction (GEJ) cancer.

Dr. Chau on Findings of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

Ian Chau, MD

February 9th 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses finding with the combination of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

Ian Chau, MD

January 23rd 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

Ian Chau, MD

March 10th 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer

Ian Chau, MD

January 21st 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.